View Guidelines Below:

Main Topics

• Acquired Bleeding Disorders
• Arterial Thromboembolism
• Coagulation & Natural Anticoagulants
• COVID and Coagulation
• Diagnostics and OMICs
• Fibrinolysis and Proteolysis
• Hemophilia and Rare Bleeding Disorders
• Hemostatic Systems in Cancer, Inflammation and Immunity
• Pediatrics
• Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies
• Platelets and Megakaryocytes 
• Vascular Biology
• Venous Thromboembolism
• Women’s Health

​​The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

Acquired Bleeding Disorders

• Coagulopathy of Major Bleeding (Trauma, PPH, Vascular/surgical, ECMO, GI bleeding, etc.)
• Management/Treatments of Acquired Bleeding
• Novel Therapies in the Management of Acquired Bleeding

Arterial Thromboembolism

• Acute Coronary Syndromes
• Atherosclerosis
• Atrial Fibrillation
• Cardiovascular Risk Factors
• Cerebrovascular Disorders
• Peripheral Artery Disease

Coagulation and Natural Anticoagulants

• Animal Models in Thrombosis and Hemostasis
• Coagulation Factors and Inhibitors
• Contact Pathway
• Critical Care and Perioperative
• FVIII/IX
• Hemostasis and Organ Dysfunction
• Microparticles
• Protein C Pathway
• Regulation of Coagulation
• Tissue Factor Pathway

COVID and Coagulation

• COVID and Coagulation, Basic Science
• COVID and Coagulation, Clinical

Diagnostics and OMICs

• Biomarkers of Thrombosis and Hemostasis
• Blood Components and Management
• Cellular Therapies
• Epigenetics, OMICs and Bioinformatics
• Laboratory Diagnostics
• Nanotechnology and Novel Biomolecules

Fibrinolysis and Proteolysis

• Fibrinogen and Factor XIII
• Fibrinolytic Factors and Inhibitors
• Plasminogen Activation in the CNS and Immunity
• Thrombolytic Therapy

Hemophilia and Rare Bleeding Disorders

• Acquired Hemorrhagic Coagulation Disorders
• Disseminated Intravascular Coagulation
• Hemophilia - Basic
• Hemophilia - Clinical
• Hemophilia - Gene Therapy
• Management of Bleeding and Trauma
• Novel Biotherapeutics in Hemophilia
• Rare Bleeding Disorders

Hemostatic System in Cancer, Inflammation and Immunity

• Coagulation Proteins Beyond Hemostasis
• Complement and Hemostatic System
• Infection and Hemostatic Factors
• Platelets and Cancer
• Platelets and Infection
• Platelets and Inflammation
• Proteases and Cancer

Nurses and Allied Health

• Nurses and Allied Health

Pediatrics

• Bleeding in Neonates and Children
• Thrombosis in Neonates and Children

Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies

• Acquired Thrombocytopenias
• ADAMTS13 and TTP
• Antiplatelet Therapy
• HIT
• HUS
• Inherited Thrombocytopenias
• Non HUS/TTP Microangiopathies
• Platelet Antagonists and Novel Therapeutics
• Platelet Function Disorders, Acquired
• Platelet Function Disorders, Hereditary
• von Willebrand Factor Biology
• VWF and von Willebrand Factor Disorders - Clinical Conditions

Platelets and Megakaryocytes

• Megakaryocytes and Thrombopoiesis
• Platelet Function and Interactions
• Platelet Proteomics and Genomics
• Platelet Receptors
• Platelet Signaling

Vascular Biology

• Blood Cells and Vessel Wall
• Endothelial Cell Signaling
• Inflammation and Sepsis
• Innate and Adaptive Immunity
• Non-coding RNAs
• Protease Activated Receptors
• Stem Cells and Vascular Cell Growth

Venous Thromboembolism

• Antiphospholipid Syndrome
• Artificial Valves
• Cancer Associated Thrombosis
• Genetic Risk Factors of Thrombosis
• Post-thrombotic Syndrome
• Thrombophilia
• Visceral Vein Thrombosis
• VTE Diagnosis
• VTE Epidemiology
• VTE Prophylaxis
• VTE Treatment

Women's Health

• Estrogens and Progestinics
• Pregnancy and Pregnancy Complications

How to Submit an Abstract

• Delegates, who would like to present their work at the congress, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee.
• ISTH Members and Non-Members are invited to submit abstracts.
• There are no fees to submit an abstract.
• Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISTH 2022 Congress website. Abstracts sent by post or email will not be accepted. No exceptions will be made.
• The submitter will be required to login with your ISTH Member login credentials or create a user account in order to submit an abstract. Once logged in you will be able to submit your abstract.
• Abstracts can be saved in "Draft” status and be re-edited and modified until the submission deadline (February 1, 2022, 17:00 Eastern Standard Time (U.S.).
  • ou can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.
• The submitted/draft abstracts cannot be edited after the submission deadline.
• Only abstracts that have been submitted properly will be considered for the congress.
• Any technical questions regarding the submission website should be sent to abstracts@isth.org.

General Guidelines

• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
• Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.
• Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.
• Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected. Similarly, do not submit a copy or close copy of an abstract under more than one (1) topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.
• All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.
• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.